Kyowa Kirin

The Japanese pharmaceutical company has its research focus in the fields of nephrology, immunology/allergology, oncology and neurology.  In particular, Kyowa Kirin also has many years of experience in the development and production of therapeutic antibodies. These bind to the tumour-infected cells and trigger a cell-mediated anti-tumour response there. This makes it possible to combat tumours very effectively and with fewer side effects than conventional methods such as radiotherapy or chemotherapy. Swissmedic has approved a new antibody therapy from Kyowa Kirin against cutaneous T-cell lymphoma (CTCL) in Switzerland in 2022.

Life Science Communication is supporting Kyowa Kirin in the Swiss market launch in the field of specialist communication. The specialist media campaign included the organisation of a media round table with key opinion leaders from the field of oncology, the preparation and dispatch of media documentation and the placement of editorial contributions and advertisements in specialist oncology and dermatology media.